Infliximab (Remicade) for ulcerative colitis - horizon scanning review
NHSC
Record ID 32005001217
English
Authors' objectives:
This study aims to summarise the currently available evidence on Infliximab (Remicade) for ulcerative colitis.
Authors' recommendations:
Infliximab (Remicade), an anti-tumor necrosis factor (TNF) agent, is in development for the treatment of active ulcerative colitis (UC). Two phase III trials (364 patients in each) that reported at conference in May 2005, demonstrated that infliximab met its primary and secondary endpoints of clinical response, clinical remission and mucosal healing in patients with moderate to severe active UC who were unresponsive to at least one standard therapy. A double-blind trial in 45 patients demonstrated that a single infusion of infliximab is effective, at 3 months, in acutely ill in-patients with fulminant UC refractory to intravenous steroids.
Authors' methods:
Overview
Details
Project Status:
Completed
Year Published:
2005
URL for published report:
http://www.hsric.nihr.ac.uk/search
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
England, United Kingdom
MeSH Terms
- Antibodies, Monoclonal
- Tumor Necrosis Factor-alpha
- Colitis, Ulcerative
Contact
Organisation Name:
NIHR Horizon Scanning Centre
Contact Address:
The NIHR Horizon Scanning Centre, Department of Public Health, Epidemiology, and Biostatistics, School of Health and Population Sciences, University of Birmingham, 90 Vincent Drive, Edgbaston, Birmingham, B15 2SP. United Kingdom. Tel: +44 121 414 7831, Fax: +44 121 2269
Contact Name:
c.packer@bham.ac.uk
Contact Email:
c.packer@bham.ac.uk
Copyright:
National Horizon Scanning Centre (NHSC)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.